Hye-Sook Jeong

Dr. Hye-Sook Jeong

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
JYJin-Seung Yun
Jin-Seung Yun
AKA Reum Kim
A Reum Kim
SKSoo Min Kim
Soo Min Kim
ESEunkyung Shin
Eunkyung Shin
SHSang-Jun Ha
Sang-Jun Ha
HJHye-Sook Jeong
Hye-Sook Jeong
As Bacille Calmette-Guérin (BCG) vaccine’s effectiveness is limited to only children, the development of new tuberculosis (TB) vaccines is being studied using several platforms, and a novel TB vaccine that overcomes this limitation is required. In this study, we designed an effective multi-epitope vaccine against Mycobacterium tuberculosis using immunoinformatic analysis. First, we selected 11 highly antigenic proteins based on previous research: Ag85A, Ag85B, Ag85C, ESAT-6, MPT64, Rv2660c, TB10.4, HspX, GlfT2, Fas, and IniB. Among these antigens, 10 linear B-cell epitopes, 9 helper T-cell epitopes, and 16 cytotoxic T-cell epitopes were predicted to design the multi-epitope vaccine. To improve the immunogenicity of the candidate vaccine, three different adjuvants, griselimycin, human beta-defensin 3 (HBD3), and 50s ribosomal protein (50sRP), were attached with linker sequences to the vaccine model. The immunogenic, antigenic, allergenic, and physicochemical properties of the resulting designed multi-epitope vaccines were predicted in silico. Moreover, 3D structural modeling, refinement, and validation were used to select a model for further evaluation. Molecular docking analysis revealed a consistent and significant binding affinity of the candidate vaccine for toll-like receptors (TLRs), TLR-2, -3, and -4. Immune simulation performed using C-ImmSim demonstrated that three rounds of immunization with multi-epitope vaccines induced a high production of cytokines and immunoglobulins related with both cellular and humoral immune response. Moreover, we constructed vaccine candidate composed of 50sRP and evaluated its immunogenicity in a mouse model. Consequently, this in silico-engineered multi-epitope structure can elicit adaptive immune responses and represents a promising novel candidate for TB vaccine development.

24 January 2012 in Virology Journal
Verified
Journal Article
Open access
PDF file
KPKwiSung Park
KwiSung Park
SYSangGu Yeo
SangGu Yeo
HJHye-Sook Jeong
Hye-Sook Jeong
KBKyoungAh Baek
KyoungAh Baek
DKDongUk Kim
DongUk Kim
DCDooSung Cheon
DooSung Cheon
Previously, we explored the epidemic pattern and molecular characterization of noroviruses (NoVs) isolated in Chungnam, Korea in 2008, and the present study extended these observations to 2009 and 2010. In Korea, NoVs showed the seasonal prevalence from late fall to spring, and widely detected in preschool children and peoples over 60 years of age. Epidemiological pattern of NoV was similar in 2008 and in 2010, but pattern in 2009 was affected by pandemic influenza A/H1N1 2009 virus. NoV-positive samples were subjected to sequence determination of the capsid gene region, which resolved the isolated NoVs into five GI (2, 6, 7, 9 and 10) and eleven GII genotypes (1, 2, 3, 4, 6, 7, 8, 12, 13, 16 and 17). The most prevalent genotype was GII.4 and occupied 130 out of 211 NoV isolates (61.6%). Comparison of NoV GII.4 of prevalent genotype in these periods with reference strains of the same genotype was conducted to genetic analysis by a phylogenetic tree. The NoV GII.4 strains were segregated into seven distinct genetic groups, which are supported by high bootstrap values and previously reported clusters. All Korean NoV GII.4 strains belonged to either VI cluster or VII cluster. The divergence of nucleotide sequences within VI and VII intra-clusters was > 3.9% and > 3.5%, respectively. The "Chungnam(06-117)/2010" strain which was isolated in June 2010 was a variant that did not belong to cluster VI or VII and showed 5.8-8.2%, 6.2-8.1% nucleotide divergence with cluster VI and VII, respectively.

19 July 2010 in Virology Journal
Verified
Journal Article
Open access
PDF file
HLHyeok-Jin Lee
Hyeok-Jin Lee
HJHye-Sook Jeong
Hye-Sook Jeong
BCByung-Ki Cho
Byung-Ki Cho
MJMi-Jeong Ji
Mi-Jeong Ji
JKJi-Ha Kim
Ji-Ha Kim
DCDoo-Sung Cheon
Doo-Sung Cheon
Background: Hepatitis A virus (HAV) is a causative agent of acute hepatitis, which is transmitted by person-to-person contact and via the faecal-oral route. Acute HAV infection is usually confirmed by anti-HAV IgM detection. In order to detect anti-HAV IgM in the serum of patients infected with HAV, we developed a rapid assay based on immunochromatography (ICA) and evaluated the sensitivity of this assay by comparing it with a commercial microparticle enzyme immunoassay (MEIA) that is widely used for serological diagnosis. Results: The newly developed ICA showed 100% sensitivity and specificity when used to test 150 anti-HAV IgM-positive sera collected from infected patients and 75 negative sera from healthy subjects. Also, the sensitivity of ICA is about 10 times higher than MEIA used in this study by determining end point to detect independent on infected genotype of HAV. In addition, the ICA was able to detect 1 positive sample from among 50 sera from acute hepatitis patients that had tested negative for anti-HAV IgM using the MEIA. Conclusion: Conclusively, ICA for the detection of anti-HAV IgM will be very effective for rapid assay to apply clinical diagnosis and epidemiological investigation on epidemics due to the simplicity, rapidity and specificity.

24 January 2025 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
JYJin-Seung Yun
Jin-Seung Yun
ESEunkyung Shin
Eunkyung Shin
YLYoung-Ran Lee
Young-Ran Lee
JLJung-Ah Lee
Jung-Ah Lee
HLHyeokjin Lee
Hyeokjin Lee
HJHye-Sook Jeong
Hye-Sook Jeong
Introduction: The inadequate efficacy of the Bacillus Calmette–Guérin (BCG) vaccine against adult pulmonary tuberculosis (TB) necessitates the development of new and effective vaccines. Human adenovirus serotype 5 (Ad5), which induces T-cell response, is a widely used viral vector. In this study, we aimed to evaluate the efficacy of a multi-antigenic recombinant Ad5 vectored vaccine and determine the optimal immunization route for enhanced immune response against Mycobacterium tuberculosis.Methods: We constructed a multi-antigenic recombinant Ad5 vectored vaccine expressing four antigens (Ag85B-ESAT6-MPT64-Rv2660c) of M. tuberculosis (rAd-TB4), immunized with rAd-TB4 (5 × 107 infectious virus units/mouse) twice at an interval of 4 weeks starting at 10 weeks after BCG priming, and evaluated its boosting efficacy in a BCG-primed mouse model, and determined the optimal immunization route.Results: Compared with the BCG-only (2 × 105 colony forming units/mouse), subcutaneous injection of rAd-TB4 (1 × 107 infectious virus units/mL; two doses) elicited a T-cell response and cytokine production in lung lymphocytes and splenocytes. rAd-TB4 immunization significantly reduced bacterial loads and inflamed lung areas compared to BCG immunization (p < 0.01) and protected against the H37Rv challenge performed at 17 weeks of BCG priming. RNA sequencing of the whole blood of rAd-TB4-vaccinated mice collected pre- and, 1 and 4 weeks post-infection, identified differentially expressed genes associated with immune and inflammatory responses, especially those in the Wnt signaling pathway.Conclusion: Our results indicate that rAd-TB4 immunization enhances the immune response to the vaccine boosting antigens in BCG-primed mice, making it a potential adult pulmonary TB vaccine candidate.

14 May 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ESEunkyung Shin
Eunkyung Shin
JYJin-Seung Yun
Jin-Seung Yun
YLYoung-Ran Lee
Young-Ran Lee
HCHye-Ran Cha
Hye-Ran Cha
SKSoo-Min Kim
Soo-Min Kim
HJHye-Sook Jeong
Hye-Sook Jeong
Mycobacterium tuberculosis infection accounted for 1.3 million deaths worldwide in 2022. Bacillus Calmette-Guérin (BCG) is the only licensed vaccine against tuberculosis (TB); however, it has limited protective efficacy in adults. In this study, we constructed a recombinant vaccinia virus expressing Ag85B from M. tuberculosis using a novel attenuated vaccinia virus (KVAC103). We then analyzed the immunogenicity of prime-boost inoculation strategies using recombinant KVAC103 expressing Ag85B (rKVAC85B) compared to BCG. In both rKVAC85B prime-boost and BCG prime-rKVAC85B boost inoculation regimens, rKVAC85B induced the generation of specific immunoglobulin G (IgG) and secretion of interferon-γ by immune cells. In vitro analysis of Mycobacterium growth inhibition revealed a comparable immune-mediated pattern of outcomes. Furthermore, bacterial loads in the lungs were significantly lower in mice inoculated with the BCG prime-rKVAC85B boost than in the BCG-only group following a rechallenge infection with both H37Rv and HN878 strains of M. tuberculosis. These findings collectively suggest that KVAC103, incorporated into a viral vector, is a promising candidate for the development of a novel TB vaccine platform that is effective against multiple M. tuberculosis strains, including H37Rv and HN878, and that rKVAC85B effectively stimulates immune responses against M. tuberculosis infection.

5 January 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
JCJu-Yeon Choi
Ju-Yeon Choi
SKSu-Hwan Kim
Su-Hwan Kim
SPSoyoung Park
Soyoung Park
HJHye Min Jang
Hye Min Jang
YLYoung Jae Lee
Young Jae Lee
HJHye-Sook Jeong
Hye-Sook Jeong
The updated JN.1 monovalent vaccine (MoV) for the 2024–2025 season elicits strong cross-neutralizing activity against subsequently circulating SARS-CoV-2 variants in 2025, including the recently emerging NB.1.8.1, with titer increases comparable to those against the vaccine strain JN.1. The immune response induced by the JN.1 MoV was markedly stronger than that induced by XBB.1.5 MoV in the previous season, both against the vaccine strain and post-vaccine variant (all P < 0.001). These results likely reflect improved background immunity to circulating variants and support the use of catch-up booster vaccination during the summer surge, particularly for high-risk groups.